Новые возможности противовоспалительной терапии хронической обструктивной болезни легких


https://doi.org/10.18093/0869-0189-2013-0-4-95-101

Полный текст:


Аннотация

Новые возможности противовоспалительной терапии хронической обструктивной болезни легких.


Об авторе

С. Н. Авдеев
ФБГУ "НИИ пульмонологии" ФМБА России
Россия

д. м. н., профессор, руководитель клинического отдела 

105077, Россия, Москва, ул. 11-я Парковая, 32, корп. 4. Тел. / факс: (495) 465-52-64.



Список литературы

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2013. www.goldcopd.org

2. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.

3. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.

4. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. 2003; 22: 672–688.

5. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709–721.

6. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 269–280.

7. Barnes P.J. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999; 54: 245–252.

8. Meshi B., Vitalis T.Z., Ionescu D. et al. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am. J. Respir. Cell. Mol. Biol. 2002; 26: 52–57.

9. Ito K., Lim S., Caramori G. et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001; 15: 1100–1102.

10. Martin C., Frija J., Burgel P.3R. Dysfunctional lung anatomy and small airways degeneration in COPD. Int. J. COPD 2013; 8: 7–13.

11. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709–721.

12. Rutgers S.R., Postma D.S., ten Hacken N.H. et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12–18.

13. Jen R., Rennard S.I., Sin D.D. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int. J. COPD 2012; 7: 587–595.

14. Antoniu S.A. New therapeutic options in the management of COPD – focus on roflumilast. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 147–155.

15. Hatzelmann A., Morcillo E.J., Lungarella G. et al. The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2010; 23: 235–256.

16. Grootendorst D.C., Gauw S.A., Verhoosel R.M. et al. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax 2007; 62: 1081–1087.

17. Rabe K.F., Bateman E.D., O'Donnell D. et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005; 366: 563–571.

18. Kardos P., Makros I., Vogelmeier C. Effect of roflumilast on quality of life in frequent and infrequent exacerbators. In: ERS Annual congress. 2013. P4150.

19. Calverley P.M., Sanchez3Toril F., McIvor A. et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 154–161.

20. Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–694.

21. Wedzicha J.A., Rabe K.F., Martinez F.J. et al. Roflumilast for the frequent exacerbator phenotype. Chest 2013; 143: 1302–1311.

22. Fabbri L.M., Calverley P.M., Izquierdo3Alonso J.L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695–703.

23. Rennard S.I., Calverley P.M.A., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir. Res. 2011, 12: 18.

24. Calverley P., Fabbri L., Martinez F. et al. Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD. In: ERS Annual congress. 2013. P3034.

25. Oba Y., Lone N.A. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ther. Adv. Respir. Dis. 2013; 7: 13–24.

26. FDA. Centre for Drug Evaluation and Research. Application number 022522Orig1s000. Medical Review(s). Available at http://wwwaccessdatafdagov/drugsatfda-docs/nda/2011/022522Orig1s000MedRpdf.

27. Tenor H., Beume R., Lahu G. et al. Pharmacology, clinical efficacy and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. In: Francis S.H. et al., eds. In: Phosphodiesterases as drug targets. Handbook of experimental pharmacology. Berlin Heidelberg: Springer-Verlag; 2011.

28. Карпечкина Ю.Л. Распространенность, особенности клинического течения и лечения ХОБЛ на фоне метаболического синдрома: клинико-патогенетическое исследование: Автореф. дис. … канд. мед. наук. М.; 2010.

29. Akpinar E.E., Akpinar S., Ertek S. et al. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk. Toraks. 2012; 60: 230–237.

30. Visser M., Bouter L.M., McQuillan G.M. et al. Elevated C-reactive protein levels in overweight and obese adults. J.A.M.A. 1999; 282: 2131–2135.

31. Rexrode K.M., Pradhan A., Manson J.E. et al. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 2003; 13: 674–682.

32. Martinez F., Rabe K., Wouters E. et al. Time course and reversibility of weight decrease with roflumilast, a phosphodiesterase inhibitor. Am. J. Respir. Crit. Care Med. 2010; 181: A4441.

33. Wouters E.F., Bredenbroker D., Teichmann P. et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J. Clin. Endocrinol. 2012; 97: E1720–E1725.

34. Wouters E.F.M., Teichmann P., Brose M. et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on glucose homeostasis in patients with treatment-naive diabetes (type 2). Am. J. Respir. Crit. Care Med. 2010; 181: A4471.

35. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809–814.

36. Janssens J.P., Herrmann F., MacGee W., Michel J.P. Cause of death in older patients with anatomo-pathological evidence of chronic bronchitis or emphysema: a case-control study based on autopsy findings. J. Am. Geriatr. Soc. 2001; 49: 571–576.

37. Rutten F.H., Moons K.G., Cramer M.J. et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross-sectional diagnostic study. Br. Med. J. 2005; 331: 1379.

38. Engstrom G., Wollmer P., Hedblad B. et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914", Malmö , Sweden. Circulation 2001; 103: 3086–3091.

39. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 26400–2646.

40. Rosengren A., Wilhelmsen L. Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int. J. Epidemiol. 1998; 27: 962–969.

41. Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.

42. Wieshammer S., Dreyhaupt J., Basler B. A Link between impaired lung function and increased cardiac stress. Respiration 2010; 79: 355–362.

43. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514–1519.

44. Tashkin D.P., Celli B., Senn S. et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.

45. Calverley P.M., Anderson J.A., Celli B. et al. TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65: 719–725.

46. Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.

47. White W.B., Cooke G.E., Kowey P.R. et al. Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease. Chest 2013; 144: 758–765.

48. Takabatake N., Nakamura H., Abe S. et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1179–1184.

49. Eid A.A., Ionescu A.A., Nixon L.S. et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1414–1418.

50. Schols A.M., Buurman W.A., Staal van den Brekl A.J. et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819–824.

51. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 2001; 297: 267–279.

52. Bundschuh D.S., Eltze M., Barsig J. et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 2001; 297: 280–290.

53. Barnes N.C., Qiu Y.3S., Pavord I.D. et al. Antiinflammatory effects of salmeterol / fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736–743.

54. Kardos P., Makros I., Vogelmeier C. Effect of roflumilast on quality of life in frequent and infrequent exacerbators. ERS Annual Congress 2013: P4150.


Дополнительные файлы

Для цитирования: Авдеев С.Н. Новые возможности противовоспалительной терапии хронической обструктивной болезни легких.  Пульмонология. 2013;(4):95-101. https://doi.org/10.18093/0869-0189-2013-0-4-95-101

For citation: Avdeev S.N. Novel effects of antiinflammatory therapy of chronic obstructive pulmonary disease. Russian Pulmonology. 2013;(4):95-101. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-4-95-101

Просмотров: 301

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)